EXTENDED REPORT

¹ Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
² Rheumatic Diseases Unit, University of Cape Town School of Medicine, Cape Town, South Africa
³ Department of Autoimmune Diseases, Institut Clínic d’Infeccions i Immunologia, Hospital Clinic, Barcelona, Catalonia, Spain
⁴ Department of Internal Medicine, Hôpital Pitié-Salpêtriére, Paris, France

Correspondence to:
Correspondence to:
Dr D Erkan, Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA;
derkan{at}pol.net

Background: Catastrophic antiphospholipid syndrome (APS) is defined as life threatening multiple organ thromboses developing simultaneously or over a short period. The survival rate of catastrophic APS is about 50%, but the long term outcome of patients who survive is unknown.

Objective: To determine the long term outcome of patients with catastrophic APS and provide further information on patients who survived.

Patients and methods: The clinical characteristics and outcomes of 130 patients with catastrophic APS have been reported previously. Six new cases were recently added to this series. Based on these publications, the authors who reported patients who had survived were contacted. Each author was asked (a) what treatment they gave their patients after the catastrophic APS; (b) if their patients had any further thrombosis.

Results: 63/136 (46%) patients died at the initial event. Of the remaining 73 patients, information was available for 58 (79%). Thirty eight (66%) patients did not develop further APS related events during an average follow up of 67.2 months. Eleven (19%) patients developed further APS related events but were still alive. No patients developed further catastrophic APS. Nine (16%) patients died: due to multiple organ failure (three patients); myelofibrosis (one); pneumonia (one); and APS related events (four).

Conclusion: Sixty six per cent of patients who survive an initial catastrophic APS event remained symptom free with anticoagulation during an average follow up of 67.2 months. Twenty six per cent of the survivors developed further APS related events and the mortality rate of these patients was about 25%.

Keywords: antiphospholipid syndrome; outcome

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Bucciarelli, S, Espinosa, G, Cervera, R (2009). The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 18: 905-912 [Abstract]  
• Avcin, T., Cimaz, R., Silverman, E. D., Cervera, R., Gattorno, M., Garay, S., Berkun, Y., Sztajnbok, F. R., Silva, C. A., Campos, L. M., Saad-Magalhaes, C., Rigante, D., Ravelli, A., Martini, A., Rozman, B., Meroni, P. L. (2008). Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics 122: e1100-e1107 [Abstract] [Full Text]  
• Magee, C. C., Coggins, M. P., Foster, C. S., Muse, V. V., Colvin, R. B. (2008). Case 2-2008 -- A 38-Year-Old Woman with Postpartum Visual Loss, Shortness of Breath, and Renal Failure. NEJM 358: 275-289 [Full Text]  
• Vora, S. K., Asherson, R. A., Erkan, D. (2006). Catastrophic Antiphospholipid Syndrome. J Intensive Care Med 21: 144-159 [Abstract]  
• Navarrete, N, Macias, P, Jaen, F, Hidalgo, C, Caliz, R, Jimenez-Alonso, J (2005). Two cases of catastrophic antiphospholipid syndrome. Lupus 14: 907-909 [Abstract]  
• Cervera, R, Font, J, Gomez-Puerta, J A, Espinosa, G, Cucho, M, Bucciarelli, S, Ramos-Casals, M, Ingelmo, M, Piette, J-C, Shoenfeld, Y, Asherson, R A, for the Catastrophic Antiphospholipid Syndrome Reg, (2005). Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64: 1205-1209 [Abstract] [Full Text]  
• Ortel, T. L. (2005). Thrombosis and the Antiphospholipid Syndrome. ASH Education Book 2005: 462-468 [Abstract] [Full Text]  
• Yagi, K, Kawano, M, Haraki, T, Higashikata, T, Ueda, K, Okada, T, Koni, I, Mabuchi, H (2004). Long-term efficacy of immunoadsorbent plasmapheresis in a patient with Budd-Chiari syndrome due to antiphospholipid syndrome: case report with nine-year follow-up. Lupus 13: 135-138 [Abstract]